Virax Biolabs Group Limited (NASDAQ:VRAX) Sees Large Growth in Short Interest

Virax Biolabs Group Limited (NASDAQ:VRAX) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 12,000 shares, an increase of 300.0% from the March 31st total of 3,000 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average trading volume of 73,000 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned about 7.87% of Virax Biolabs Group at the end of the most recent quarter. Hedge funds and other institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Stock Performance

NASDAQ:VRAX opened at $0.70 on Friday. The company has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $1.46. Virax Biolabs Group has a 52 week low of $0.61 and a 52 week high of $5.45.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.